Project Grant HT94252310849
Award Date
9/29/23
Completion Date
9/28/25
Dollars Obligated
$385K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
The University of Sydney, under a $1,352,341 project grant from the Department of the Army Medical Command's Military Medical Research and Development (CFDA 12.420) program, is conducting a comparative effectiveness study on exercise, cognitive behavioral therapy, and their combination for people with chronic musculoskeletal pain and poor sleep. This 4-year project, running from September 2024 to September 2028, aims to investigate innovative approaches to improving health outcomes for...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $674,746 Project Grant to the Seattle Institute for Biomedical and Clinical Research. The grant, titled "GLIMPSE-PD: GLYMPHATICS IMAGING TO PROBE SLEEP IN PARKINSON'S DISEASE", aims to investigate glymphatic function and sleep disruption in Parkinson's disease. The research will leverage expertise and resources from the University of Washington, where a $214,688 sub-award...
The University of Sydney was awarded a $3,580,840 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "HEROIC PROSTATE CANCER PRECISION HEALTH (PCAPH) AFRICA1K: POWERING PRECISION HEALTH TO IMPROVE PROSTATE CANCER OUTCOMES IN AFRICA", aims to conduct advanced biomedical research to transform healthcare for military service members and the broader public. The research will focus on...
The University of Sydney, doing business as the International Clinical Trials Symposium, was awarded a $632,080 Project Grant on July 1, 2025 from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant will fund research to investigate "THE X FACTOR: WHAT ENDOWS WOMEN WITH A BETTER CHANCE OF SURVIVAL FROM MELANOMA?" over a period of 3 years, with a final completion date of June 30, 2028. The Military...
The Department of the Army Medical Command has awarded a $1,173,445 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Council of the Queensland Institute of Medical Research, doing business as QIMR Berghofer Medical Research Institute, in Australia. The grant, awarded on September 1, 2024, will fund a research project titled "The Nose Knows: Harnessing Human Olfactory Cells to Identify Biomarkers of Nonmotor Changes in Parkinson's...
The Department of the Army Medical Command awarded a $1,126,472 project grant under the Military Medical Research and Development (CFDA 12.420) program to The University of Auckland in New Zealand. The purpose of the grant is to identify the earliest druggable targets for Parkinson's disease. The award has a performance period from September 1, 2024 to August 31, 2027. As a prominent international research institution, The University of Auckland has established a strong track record of...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,047,751 Project Grant to the Portland VA Research Foundation, Inc. to conduct the "GLIMPSE-PD: GLYMPHATICS IMAGING TO PROBE SLEEP IN PARKINSON'S DISEASE" research project. This 4-year award, beginning on Sep 1, 2024 and ending on Aug 31, 2028, will enable the Portland VA Research Foundation to carry out scientific research aimed at improving health outcomes for...
The University of Sydney was awarded a $919,739 Project Grant from the Department of the Army Medical Command through its Military Medical Research and Development program (CFDA 12.420). The grant will fund a molecular epidemiological study from September 2021 through September 2025 examining the relationship between aspirin and NSAID use and ovarian cancer prognosis. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The federal Project Grant award of $659,922.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a gene therapy research project at Macquarie University in Australia. The project aims to develop a gene therapy for nuclear TDP-43 supplementation as a pathway to delaying the onset of neurodegenerative disease. The award period spans from September 15, 2025 to September 14, 2027. As an internationally recognized research institution,...
This federal Project Grant award of $1,021,409.00 from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Illinois to investigate the underlying neurobiology of non-motor symptoms in Parkinson's disease. The research aims to elucidate the role of serotonin system plasticity in the development of these disabling non-motor complications, which can include cognitive, psychiatric, and...